GSK548470 300 mg tablet

DRUG2 trials

Sponsors

GlaxoSmithKline

Conditions

Hepatitis B, Chronic

Phase 3

Phase 3 Study of GSK548470 in Patients With Compensated Chronic Hepatitis B With Poor Response to Other Drugs

CompletedNCT01475851

GlaxoSmithKlineHepatitis B, Chronic

Start: 2011-12-31End: 2014-10-31Updated: 2015-06-22

Phase 3 Study of GSK548470 in Patients With Compensated Chronic Hepatitis B Untreated With Nucleic Acid Analogue

CompletedNCT01480284

GlaxoSmithKlineHepatitis B, Chronic

Start: 2011-11-30End: 2014-11-30Updated: 2016-08-10

Related Papers

Randomized prospective study showing the non‐inferiority of tenofovir to entecavir in treatment‐naïve chronic hepatitis B patients

Hepatology Research2017-04-0570 citations

Efficacy and safety of tenofovir disoproxil fumarate rescue therapy for chronic hepatitis B patients who failed other nucleos(t)ide analogs

Hepatology Research2016-11-1611 citations